Jafron Biomedical Co

Jafron Biomedical Co EBITDA Margin

The EBITDA Margin of Jafron Biomedical Co (300529.SZ) as of Nov 20, 2026 is 36.76 %. In the previous year, EBITDA Margin was 41.53 % — a change of -11.49% (lower).

EBITDA Margin

36.76 %

YoY

-11.49%

Last updated:

EBITDA Margin of Jafron Biomedical Co is 2025 36.76 % . EBITDA Margin of Jafron Biomedical Co was 2024 41.53 % . It decreases by -11.49% lower compared to the previous year.

The Jafron Biomedical Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
47.84 CNY
Jan 1, 2019
48.45 CNY
Jan 1, 2020
54.93 CNY
Jan 1, 2021
54.15 CNY
Jan 1, 2022
42.95 CNY
Jan 1, 2023
31.22 CNY
Jan 1, 2024
41.53 CNY
Jan 1, 2025
36.76 CNY
The Jafron Biomedical Co EBITDA Margin history
YEAREBITDA MarginYoY
36.76 %-11.49%
41.53 %+33.04%
31.22 %-27.31%
42.95 %-20.69%
54.15 %-1.42%
54.93 %+13.37%
48.45 %+1.27%
47.84 %+1.63%
47.07 %+7.09%
43.96 %-5.35%
46.44 %-2.09%
47.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

EBITDA Margin of Jafron Biomedical Co is 36.76 % in 2025.

EBITDA Margin of Jafron Biomedical Co changed from 41.53 % to 36.76 %, representing a -11.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co